Three years ago Mark Kay, MD, PhD, published the first results showing that a biological phenomenon called RNA interference could be an effective gene therapy technique. Since then he has used RNAi gene therapy to effectively shut down the viruses that cause hepatitis and HIV in mice.
With three human RNAi gene therapy trials now under way - two in macular degeneration and one in RSV pneumonia - the technique Kay pioneered may be among the first to find widespread use for treating human diseases. "We've worked on a gene therapeutic approach against viral hepatitis for about 10 years and this is the first thing we've done that really looks promising," said Kay, professor of genetics and of pediatrics at the Stanford University School of Medicine.
Kay will talk about future uses for RNAi gene therapy at the American Association for the Advancement of Sciences annual meeting in San Francisco during a session titled "RNAi for emerging pandemics and biosecurity."
RNAi is a biological phenomenon in which a strand of RNA in the cell can cause the destruction of another strand of RNA that is relaying a protein-coding message from a gene. With that protein-coding message removed, the gene's message is effectively destroyed. When used as gene therapy, RNAi turns off genes that are overactive in such diseases as cancer or macular degeneration, or disables genes needed by an invading virus. With key genes shut off, viruses such as hepatitis or HIV are unable to multiply and cause disease.
In early RNAi experiments, researchers saw some hints that the technique could induce an immune reaction or switch off the wrong gene or genes. In work last year, Kay confirmed those findings but also showed a possible way around those toxic effects by selecting particular RNA sequences.
"One benefit of RNAi gene therapy is that it uses the body's own machinery, making it an effective approach," Kay said at the time. "However, the detriment of RNAi gene therapy turns out to be that it uses the body's own machinery." He said he expects the current trials will help him and others figure out the best way to bring RNAi gene therapy safely to humans.
Source: Stanford University
Related stories:
First gene associated with dry macular degeneration found
In a study that underscores the important role that individual genetic profiles will play in the development of new therapies for disease, a multi-institutional research team – led by Kang Zhang, MD, PhD professor of ophthalmology and human genetics at Shiley Eye Center at the University of California, San Diego, School of Medicine – has made two important discoveries related to age-related macular degeneration (AMD), the leading cause of blindness in adults over the age of 60.
'Silencing' HIV with small bits of RNA
Researchers have shown that they can effectively tackle HIV-1 with small bits of gene-silencing RNA by delivering them directly to infected T cells, the major targets of the virus. While earlier studies had shown such a strategy could fight against many viruses including HIV-1, the new study in mice with human blood cells, so-called humanized mice, is the first to demonstrate an effective approach to systemic delivery in a living animal.
Genes that control embryonic stem cell fate identified
Scientists have identified about two dozen genes that control embryonic stem cell fate. The genes may either prod or restrain stem cells from drifting into a kind of limbo, they suspect. The limbo lies between the embryonic stage and fully differentiated, or specialized, cells, such as bone, muscle or fat.
Inhalable form of gene-therapy takes aim at lung cancer and inflammatory lung disease
A new inhalable form of gene therapy — based on technology recognized in the 2006 Nobel medicine prize, shows increasing promise for treating lung cancer, infectious diseases and inflammatory lung disease, scientists have concluded after an exhaustive review of worldwide research on the topic. Their report is scheduled for the June 2 issue of ACS'
Molecular Pharmaceutics.
Team develops safe, effective RNA interference technique
A team of researchers from MIT and Alnylam Pharmaceuticals has developed safe and effective methods to perform RNA interference, a therapy that holds great promise for treating a variety of diseases including cancer and hepatitis.
Physician revolutionizes gene research
A dramatic new study published in the most recent issue of
Nature questions some of the mechanisms underlying a new class of drugs based on Nobel Prize-winning work designed to fight diseases ranging from macular degeneration to diabetes.
The RNA drug revolution -- a new approach to gene therapy
RNA interference (RNAi) represents an innovative new strategy for using small RNA molecules to silence specific genes associated with disease processes, and a series of review articles describing the state-of-the-art and potential therapeutic applications of RNAi and microRNAs will begin with two review papers in the January 2008 issue (Volume 19, Number 1) of
Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. The papers are available free online.
Genetic approach provides new insight into trastuzumab resistance in breast cancer
A new study provides important insight into the mechanisms involved in resistance to treatment of breast cancer patients with trastuzumab (Herceptin). The research, published by Cell Press in the October issue of the journal
Cancer Cell, identifies markers that may help to identify patients who are unlikely to respond to trastuzumab treatment and provides a potential strategy for treating these patients.